Skip to main content
SpringerLink
Log in

Safety, Tolerability and Pharmacokinetic Profile of BIA 2-093, a Novel Putative Antiepileptic Agent, during First Administration to Humans

  • Original Research Article
  • Published:
Drugs in R & D Aims and scope Submit manuscript

Abstract

Objective: To evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of BIA 2-093 [S-(−)-10-acetoxy-10,11-dihydro-5H-dibenzo/b,f/azepine- 5-carboxamide] in healthy male volunteers.

Design: This was a double-blind, randomised, placebo-controlled, single ascending dose study performed with BIA 2-093, a new putative antiepileptic drug.

Participants and methods: Groups of eight healthy male subjects (two randomised to receive placebo and the remaining six to receive BIA 2-093) received single oral doses of BIA 2-093 of 20, 50, 100, 200, 400, 600, 900 and 1200mg. A total of 64 healthy male volunteers aged 18–35 years participated in the study.

Results: The incidence of adverse events, which were mild in severity, was similar between all treatment groups, including the placebo group. There were no serious adverse events during this study. No clinically significant abnormalities in laboratory safety tests, vital signs, weight, physical examination or ECG were reported. BIA 2-093 appeared to be rapidly and extensively metabolised to BIA 2-005 [RS(±)-10,11-dihydro-10-hydroxy-5H-dibenzo/b,f/azepine-5-carboxamide], the major metabolite, and oxcarbazepine (the minor metabolite), following single oral doses of BIA 2-093 of 20–1200mg. Plasma BIA 2-093 concentrations were generally below the limit of quantification of the assay. Maximum plasma concentrations (Cmax) of BIA 2-005 and oxcarbazepine were reached, respectively, at 0.75–4h and 6h postdose, after which they declined with an approximate mean apparent terminal half-life of 8–17h and 7–12h, respectively. The increase in systemic exposure to BIA 2-005 was approximately proportional to the administered dose for Cmax and greater than dose proportional for the area under the concentration-time curve. Renal clearance of BIA 2-005 (20 mL/ min) appeared to be constant over the dose range studied, indicating that the dose-dependent urinary recovery was due either to increased formation of BIA 2-005 with increasing dose level or to decreased non-renal elimination of the metabolite.

Conclusion: BIA 2-093 undergoes extensive metabolism to BIA 2-005 and was well tolerated at oral doses of 20–1200mg. The results provide a basis for further clinical trials with BIA 2-093.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Table I
Fig. 2
Fig. 3
Table II
Table III
Fig. 4
Table IV
Table V

Similar content being viewed by others

References

  1. Sander JW, Shorvon SD. Incidence and prevalence studies in epilepsy and their methodological problems: a review. J Neurol Neurosurg Psychiatry 1987; 50: 829–39

    Article  PubMed  CAS  Google Scholar 

  2. Upton N. Mechanisms of action of new antiepileptic drugs: rational design and serendipitous findings. Trends Pharmacol Sci 1994; 15: 456–63

    Article  PubMed  CAS  Google Scholar 

  3. Perucca E. The new generation of antiepileptic drugs: advantages and disadvantages. Br J Clin Pharmacol 1996; 42: 531–43

    PubMed  CAS  Google Scholar 

  4. Schmidt D, Morselli PL. Intractable epilepsy: experimental and clinical aspects. New York: Raven Press, 1986

    Google Scholar 

  5. Shorvon SD. The epidemiology and treatment of chronic and refractory epilepsy. Epilepsia 1996; 37 Suppl. 2: 1–3

    Article  Google Scholar 

  6. Schmidt D. Meyler’s side effects of drugs. 12th ed. Amsterdam: Elsevier Science, 1992

    Google Scholar 

  7. Benes J, Parada A, Figueiredo AA, et al. Anticonvulsant and sodium channel-blocking properties of novel 10,11-dihy-dro-5H-dibenz[b,f]azepine-5-carboxamide derivatives. J Med Chem 1999; 42: 2582–7

    Article  PubMed  CAS  Google Scholar 

  8. Hainzl D, Parada A, Soares-da-Silva P. Metabolism of two new antiepileptic drugs and their principal metabolites S(+)- and R(−)-10,11-dihydro-10-hydroxy carbamazepine. Epilepsy Res 2001; 44: 197–206

    Article  PubMed  CAS  Google Scholar 

  9. Ambrosio AF, Soares-Da-Silva P, Carvalho CM, et al. Mechanisms of action of carbamazepine and its derivatives, ox-carbazepine, BIA 2-093, and BIA 2-024. Neurochem Res 2002; 27: 121–30

    Article  PubMed  CAS  Google Scholar 

  10. Ambrosio AF, Silva AP, Malva JO, et al. Inhibition of glutamate release by BIA 2-093 and BIA 2-024, two novel derivatives of carbamazepine, due to blockade of sodium but not calcium channels. Biochem Pharmacol 2001; 61: 1271–5

    Article  PubMed  CAS  Google Scholar 

  11. Parada A, Soares-da-Silva P. The novel anticonvulsant BIA 2-093 inhibits transmitter release during opening of voltage-gated sodium channels: a comparison with carbamazepine and oxcarbazepine. Neurochem Int 2002; 40: 43–40

    Article  Google Scholar 

  12. Bonifacio MJ, Sheridan RD, Parada A, et al. Interaction of the novel anticonvulsant, BIA 2-093, with voltage-gated sodium channels: comparison with carbamazepine. Epilepsia 2001; 42: 600–8

    Article  PubMed  CAS  Google Scholar 

  13. Ambrosio AF, Silva AP, Araujo I, et al. Neurotoxic/neuroprotective profile of carbamazepine, oxcarbazepine and two new putative antiepileptic drugs, BIA 2-093 and BIA 2-024. Eur J Pharmacol 2000; 406: 191–201

    Article  PubMed  CAS  Google Scholar 

  14. Bond A, Lader M. The use of analogue scales in rating subjective feelings. Br J Med Psychol 1974; 47: 211–8

    Article  Google Scholar 

  15. Gough K, Hutchison M, Keene O, et al. Assessment of dose proportionality: report from the statisticians in the pharmaceutical industry/pharmacokinetics UK joint working party. Drug Inform J 1995; 29: 1039–48

    Article  Google Scholar 

  16. Feldmann KF, Brechbühler S, Faigle JW, et al. Pharmacokinetics and metabolism of GP 47 680, a compound related to carbamazepine, in animals and man. In: Meinardi H, Rowan AJ, editors. Advances in epileptology. Amsterdam/Lisse: Swets & Zeitlinger, 1978: 290–294

    Google Scholar 

  17. Feldmann KF, Dörrhöfer G, Faigle JW, et al. Pharmacokinetics and metabolism of GP 47 779, the main human metabolite of oxcarbazepine (GP 47 680) in animals and healthy volunteers. In: Dam M, editor. Advances in epileptology: XIIth Epilepsy Intern. Symp. New York: Raven Press, 1981: 89–96

    Google Scholar 

  18. Faigle JW, Menge GP. Metabolic characteristics of ox-carbazepine and their clinical significance: comparison with carbamazepine. Behav Neurol 1990; 3 Suppl. 1: 21–30

    Google Scholar 

  19. Schutz H, Feldmann KF, Faigle JW, et al. The metabolism of 14C-oxcarbazepine in man. Xenobiotica 1986; 16: 769–78

    Article  PubMed  CAS  Google Scholar 

  20. Flesch G, Francotte E, Hell F, et al. Determination of the R-(−) and S-(+) enantiomers of the monohydroxylated metabolite of oxcarbazepine in human plasma by enantioselective highperformance liquid chromatography. J Chromatogr 1992; 581: 147–51

    Article  PubMed  CAS  Google Scholar 

  21. Volosov A, Xiaodong S, Perucca E, et al. Enantioselective pharmacokinetics of 10-hydroxycarbazepine after oral administration of oxcarbazepine to healthy Chinese subjects. Clin Pharmacol Ther 1999; 66: 547–53

    PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The study was funded by Bial (Portela & Ca SA), S. Mamede do Coronado, Portugal.

Author information

Authors and Affiliations

  1. Department of Research and Development, BIAL, À Av. da Siderurgia Nacional, 4745-457, S. Mamede do Coronado, Portugal

    Luis Almeida &  Patrício Soares-da-Silva

Authors
  1. Luis Almeida
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Patrício Soares-da-Silva
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Patrício Soares-da-Silva.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Almeida, L., Soares-da-Silva, P. Safety, Tolerability and Pharmacokinetic Profile of BIA 2-093, a Novel Putative Antiepileptic Agent, during First Administration to Humans. Drugs R&D 4, 269–284 (2003). https://doi.org/10.2165/00126839-200304050-00001

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00126839-200304050-00001

Keywords

Search

Navigation